About PILA PHARMA
PILA PHARMA is a publicly held clinical stage pharmaceutical company based in Malmö, Sweden.
The company is developing a TRPV1 antagonist, XEN-D0501, as a novel type of oral anti-diabetic agent.
XEN-D0501 is a synthetic small molecule that was in-licensed in 2016.
Prior to in-licensing, XEN-D0501 had been found to have a good safety profile in other (non-diabetic) patient groups.
PILA PHARMA has to date completed two phase 2a clinical trials (PP-CT01 and PP-CT02), that both demonstrated that XEN-D0501 is well tolerated by people with type 2 diabetes.
Further, PP-CT02, demonstrated that XEN-D0501 (administered as 4 mg BID for 28 days) – with statistical significance versus placebo – enhance the endogenous insulin response to oral glucose.
FÅ PRESSMEDDELANDEN / GET PRESS RELEASES

News
Läs pressmeddelandet (in Swedish) här
(09-May-2022)

Late last week Redeye had a brief interview with our CEO, Dorte X. Gram regarding the last quarterly report and recent significant changes and developments in Pila.
Please, find the link to the video (in English) here
(03-May-2022)
Delårsrapport 1 januari – 31 mars 2022
Läs rapporten PDF (in Swedish) här
(26-April-2022)
Läs (in Swedish) här
(05-April-2022)
Årsredovisning för 2021
Läs rapporten PDF (in Swedish) här
(23-March-2022)
The recording of our CEO Dorte X. Gram’s presentation (in Swedish) from Aktiespararna is now live.
Please, find the link to the video (in Swedish) here
(15-March-2022)
(05-March-2022)
(04-March-2022)

Please, find the link to the video (in English) here
(02-March-2022)
PILA PHARMA bokslutskommuniké för 1 januari – 31 december 2021
Läs rapporten PDF (in Swedish) här
(18-February-2022)
Please, read the article (in Swedish) here
(07-February-2022)

